Leisure Capital Management Has $3.12 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Leisure Capital Management boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,079 shares of the company’s stock after buying an additional 898 shares during the quarter. Johnson & Johnson makes up 1.9% of Leisure Capital Management’s portfolio, making the stock its 8th largest position. Leisure Capital Management’s holdings in Johnson & Johnson were worth $3,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Morton Brown Family Wealth LLC lifted its holdings in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after buying an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $39,000. Cardinal Capital Management Inc. lifted its holdings in Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after buying an additional 200 shares in the last quarter. First Bank & Trust increased its position in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares during the period. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $84,000. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

NYSE:JNJ opened at $168.31 on Tuesday. The company has a market cap of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company’s 50 day moving average is $176.07 and its two-hundred day moving average is $171.13.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Barclays began coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. Bank of America cut their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Citigroup lifted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.